Biogen Avonex Overtakes Berlex' Betaseron In Europe, Leads MS Market
Executive Summary
Biogen's Avonex currently holds 57% of the U.S. multiple sclerosis market, and has recently surpassed Berlex' Betaseron to lead the European market with a 43% share, Biogen Treasurer John Conley told analysts at the Paine Webber Growth & Technology Conference in New York City June 9.